ZYMEWORKS INC (US)(ZYME),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ZYME ZYMEWORKS INC (US)

Market Closed 02-14 16:00:00 EST

15.01

+0.39

+2.67%

盘后15.55

+0.54+3.60%

17:07 EST

High15.16	Low14.61	Vol242.32K
Open14.73	D1 Closing14.62	Amplitude3.73%
Mkt Cap1.03B	Tradable Cap591.27M	Total Shares68.88M
T/O3.63M	T/O Rate0.62%	Tradable Shares39.39M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ZYME","market":"US","secType":"STK","nameCN":"ZYMEWORKS INC (US)","latestPrice":15.01,"timestamp":1739566800000,"preClose":14.62,"halted":0,"volume":242322,"hourTrading":{"tag":"盘后","latestPrice":15.55,"preClose":15.01,"latestTime":"17:07 EST","volume":14788,"amount":222817.25,"timestamp":1739570862640},"delay":0,"floatShares":39391931,"shares":68877526,"eps":-1.517898,"marketStatus":"Market Closed","change":0.39,"latestTime":"02-14 16:00:00 EST","open":14.73,"high":15.155,"low":14.61,"amount":3625592.68536,"amplitude":0.037278,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.517898,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1739869200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1493352000000,"exchange":"NASDAQ","adjPreClose":14.62,"preHourTrading":{"tag":"盘前","latestPrice":15.01,"preClose":14.62,"latestTime":"09:09 EST","volume":434,"amount":6405.049686,"timestamp":1739542193547},"postHourTrading":{"tag":"盘后","latestPrice":15.55,"preClose":15.01,"latestTime":"17:07 EST","volume":14788,"amount":222817.25,"timestamp":1739570862640},"volumeRatio":0.5994973880517642,"impliedVol":0.9157,"impliedVolPercentile":0.7331},"requestUrl":"/m/hq/s/ZYME","defaultTab":"news","newsList":[{"id":"2506752845","title":"13D Filings -- Barron's","url":"https://stock-news.laohu8.com/highlight/detail?id=2506752845","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506752845?lang=en_us&edition=fundamental","pubTime":"2025-01-25 10:30","pubTimestamp":1737772200,"startTime":"0","endTime":"0","summary":"These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from Jan. 16 through Jan. 22, 2025. Source: VerityData. Accolade  Magnetar Financial disclosed a new position in the healthcare technology company of 5,135,671 shares. Magnetar Financial purchased those shares from Jan. 8 through Jan. 17, 2025, at per-share prices ranging from $6.83 to $6.89. Magnetar Financial is probably making an arbitrage play.Auna Grupo ngeles Servicios de Salud increased its stake in the healthcare provider to 7,214,062 shares. Grupo ngeles did so through the purchase of 554,062 Auna shares from Dec. 2, 2024, through Jan. 14, 2025, at per share prices ranging from $6.51 to $7.70.Following the latest purchases, Grupo ngeles owns 24.1% of Auna's outstanding stock. Shares of Auna h","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","BK4104","DELL","LU0757428866.USD","BK4535","BK4139","ACCD","LU1815336091.USD","BK4135","BK4185","AUNA","GATX","BK4585","BK4515","BK4543","GAMI","BK4170","LU0267386448.USD","ZYME","BK4588"],"gpt_icon":1},{"id":"2505096901","title":"The past five years for Zymeworks (NASDAQ:ZYME) investors has not been profitable","url":"https://stock-news.laohu8.com/highlight/detail?id=2505096901","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505096901?lang=en_us&edition=fundamental","pubTime":"2025-01-23 18:50","pubTimestamp":1737629422,"startTime":"0","endTime":"0","summary":"While it may not be enough for some shareholders, we think it is good to see the Zymeworks Inc.  share price up 14% in a single quarter. But that is little comfort to those holding over the last half decade, sitting on a big loss. The share price has failed to impress anyone , down a sizable 69% during that time. So we're not so sure if the recent bounce should be celebrated. Of course, this could be the start of a turnaround.It's worthwhile assessing if the company's economics have been moving in lockstep with these underwhelming shareholder returns, or if there is some disparity between the two. So let's do just that.Because Zymeworks made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually desire strong revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/past-five-years-zymeworks-nasdaq-105022506.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BGHQF748.EUR","IE00BKPKM429.USD","USJW.SI","IE00B64PRP62.GBP","LU2210149790.SGD","QID","IE00B3QW5Z07.USD","SQQQ","BK4139","ZYME","BK4588","TQQQ","NQmain","LU2210150020.SGD","NDAQ",".IXIC","NVIW.SI","QLD","TSYW.SI","BK4585","PSQ","MNQmain","USAW.SI","BK4112","LU2095319765.USD"],"gpt_icon":1},{"id":"2504140554","title":"Big Biotech Fund Bought a Stock That Surged, and a Loser -- Barron's","url":"https://stock-news.laohu8.com/highlight/detail?id=2504140554","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504140554?lang=en_us&edition=fundamental","pubTime":"2025-01-18 10:30","pubTimestamp":1737167400,"startTime":"0","endTime":"0","summary":"A big biotech investment fund plowed more money into shares of two small companies as 2024 was coming to an end and the new year was just starting.EcoR1 Capital of San Francisco paid nearly $26 million to increase its stakes in Zymeworks, which has cancer and tumor treatments in its pipeline, and AnaptysBio, which is focused on autoimmune and inflammatory diseases. It remains the largest shareholder of both companies.The stocks are coming off 2024 with markedly different outcomes. Shares of Zymeworks, which has a market capitalization of just under $1 billion, surged 41%, trouncing the 23% rise in the S&P 500. Stock of AnaptysBio, with a market cap of less than $500 million, fell 38%. The new year has seen a change with Zymeworks stock down 9.7% so far in January, and AnaptysBio stock up 7.3%.EcoR1 paid $24.7 million from Dec. 19 through Jan. 2 for a total of 1.75 million Zymeworks shares, an average price of $14.15 each. The fund now owns 15.2 million shares, according to a form it fi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANAB","ZYME","BK4139"],"gpt_icon":0},{"id":"2502351712","title":"Big Biotech Fund Loads Up on a Stock That Surged in 2024, and a Loser -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2502351712","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502351712?lang=en_us&edition=fundamental","pubTime":"2025-01-12 16:00","pubTimestamp":1736668800,"startTime":"0","endTime":"0","summary":"A big biotech investment fund plowed more money into shares of two small companies as 2024 was coming to an end and the new year was just starting.EcoR1 Capital of San Francisco paid nearly $26 million to increase its stakes in Zymeworks, which has cancer and tumor treatments in its pipeline, and AnaptysBio, which is focused on autoimmune and inflammatory diseases. It remains the largest shareholder of both companies.The stocks are coming off 2024 with markedly different outcomes. Shares of Zymeworks, which has a market capitalization of just under $1 billion, surged 41%, trouncing the 23% rise in the S&P 500. Stock of AnaptysBio, with a market cap of less than $500 million, fell 38%. The new year has seen a change with Zymeworks stock down 9.7% so far in January, and AnaptysBio stock up 7.3%.EcoR1 paid $24.7 million from Dec. 19 through Jan. 2 for a total of 1.75 million Zymeworks shares, an average price of $14.15 each. The fund now owns 15.2 million shares, according to a form it fi","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANAB","BK4139","ZYME"],"gpt_icon":0},{"id":"2502014952","title":"Zymeworks (ZYME) Receives a Buy from Stifel Nicolaus","url":"https://stock-news.laohu8.com/highlight/detail?id=2502014952","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502014952?lang=en_us&edition=fundamental","pubTime":"2025-01-09 21:06","pubTimestamp":1736427976,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on Zymeworks (ZYME – Research Report) today and set a price target of $28.00. The co...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/zymeworks-zyme-receives-a-buy-from-stifel-nicolaus-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/zymeworks-zyme-receives-a-buy-from-stifel-nicolaus-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SF","BK4139","BK4127","ZYME"],"gpt_icon":0},{"id":"2502089383","title":"Zymeworks Sees Current Cash Resources, Expected Payments to Support Operations Into H2 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2502089383","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502089383?lang=en_us&edition=fundamental","pubTime":"2025-01-09 06:04","pubTimestamp":1736373896,"startTime":"0","endTime":"0","summary":"Zymeworks  said Wednesday it exited 2024 with around $324 million in cash that should support its operations at projected levels into H2 2027, when combined with anticipated milestone payments.The $324 million cash, cash equivalent reserve on Dec. 31 does not include a $25 milestone payment due in the current quarter from Jazz Pharmaceuticals  that was triggered by approval in the US of Ziihera bispecific antibody treatment for HER2-positive biliary tract cancer.Zymeworks also said the company is well-positioned for additional progress with its drug pipeline to potential treat various autoimmune and inflammatory diseases as well as hematological cancers.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LU0320765992.SGD","ZYME","BK4533","JAZZ","BK4007","LU0109394709.USD","BK4532","LU0889565916.HKD"],"gpt_icon":0},{"id":"2502887600","title":"Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2502887600","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502887600?lang=en_us&edition=fundamental","pubTime":"2025-01-09 05:05","pubTimestamp":1736370300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250108:nTUA7CSXGB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZYME","BK4139"],"gpt_icon":0},{"id":"2502868083","title":"Zymeworks Inc - Ind Applications for ZW209 and ZW1528 Expected in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2502868083","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502868083?lang=en_us&edition=fundamental","pubTime":"2025-01-09 05:05","pubTimestamp":1736370300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250108:nTUA7CSXGB:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ZYME"],"gpt_icon":0},{"id":"2502083850","title":"Zymeworks Inc - Ind Applications for ZW220 and ZW251 in Solid Tumors Expected in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2502083850","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502083850?lang=en_us&edition=fundamental","pubTime":"2025-01-09 05:05","pubTimestamp":1736370300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250108:nTUA7CSXGB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ZYME"],"gpt_icon":0},{"id":"2500121429","title":"Landsea Homes, LandBridge, and More Stocks See Action From Activist Investors -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2500121429","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500121429?lang=en_us&edition=fundamental","pubTime":"2025-01-04 05:31","pubTimestamp":1735939860,"startTime":"0","endTime":"0","summary":"These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from Dec. 26, 2024, through Jan. 1, 2025. Source: VerityData. Landsea Homes  Mill Road Capital III disclosed a new position in the residential real estate development company of 1,818,281 shares. Mill Road Capital reported that it purchased 853,500 Landsea Homes shares from Nov. 6 through Dec. 23, 2024, at per share prices ranging from $10.25 to $12.50.Following the latest purchases, Mill Road Capital owns 5% of Landsea Homes' outstanding stock, placing it at the 5% threshold that requires it to disclose further Landsea Homes purchases or sales. Shares of Landsea Homes lost nearly a third of their value in 2024.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4213","BK4233","FOA","RMBL","BK4139","ZYME","ISBC","LSEA","BK4122","BK4088","BK4211","BK4229","LB","BK4195","BK4214"],"gpt_icon":0},{"id":"2491613908","title":"BUZZ-Zymeworks jumps after JPM upgrades stock to 'overweight'","url":"https://stock-news.laohu8.com/highlight/detail?id=2491613908","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491613908?lang=en_us&edition=fundamental","pubTime":"2024-12-16 23:44","pubTimestamp":1734363897,"startTime":"0","endTime":"0","summary":"BUZZ-Zymeworks jumps after JPM upgrades stock to 'overweight'** Cancer therapy developer Zymeworks' ZYME.O shares up as much as 10.6% to $13.91** Brokerage J.P.Morgan upgrades company's shares to \"overweight\" from \"neutral\", raises PT by $6 to $18** Recent R&D day event has brokerage more confident in company's oncology and autoimmune diseases pipeline, with two distinct TCE, ADC cancer therapies progressing in the clinics - JPM** Company's cancer drug Zani provides \"solid support\" to stock valuation - brokerage** JPM believes 2025 is the year to pay attention and could begin to see one or more of company's \"5x5\" pipeline plan succeeding in clinics** Zymeworks' internal portfolio is largely underappreciated at this level as it begins to take shape as a true \"multiple shots on goal\" story with attractive upside potential - brokerage** Brokerage Jefferies also raises PT on company's shares by $2 to $24** 6 of 8 brokerages rate the stock \"buy\" or higher, and 2 \"hold\"; median PT $18.75 - L","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241216:nL4N3NH14Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZYME"],"gpt_icon":0},{"id":"2491693513","title":"JPMorgan Upgrades Zymeworks to Overweight From Neutral, Adjusts Price Target to $18 From $12","url":"https://stock-news.laohu8.com/highlight/detail?id=2491693513","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491693513?lang=en_us&edition=fundamental","pubTime":"2024-12-16 20:58","pubTimestamp":1734353927,"startTime":"0","endTime":"0","summary":"Zymeworks (ZYME) has an average rating of overweight and mean price target of $20.19, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ba","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ZYME"],"gpt_icon":0},{"id":"2491653849","title":"Zymeworks Inc : Jefferies Raises Target Price to $24 From $22","url":"https://stock-news.laohu8.com/highlight/detail?id=2491653849","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491653849?lang=en_us&edition=fundamental","pubTime":"2024-12-16 15:34","pubTimestamp":1734334444,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241216:nFWN3NH0A6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZYME","BK4139"],"gpt_icon":0},{"id":"2491463722","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (HIMS), Zymeworks (ZYME) and Axsome Therapeutics (AXSM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2491463722","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491463722?lang=en_us&edition=fundamental","pubTime":"2024-12-16 14:30","pubTimestamp":1734330657,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Hims & Hers Health (HIMS – Research Report), Zymew...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-hims-hers-health-hims-zymeworks-zyme-and-axsome-therapeutics-axsm?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-hims-hers-health-hims-zymeworks-zyme-and-axsome-therapeutics-axsm?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4585","HIMS","HCSG","BK4137","BK4007","BK4505","ZYME","AXSM","BK4196"],"gpt_icon":0},{"id":"2491394686","title":"Zymeworks Inc : JP Morgan Raises to Overweight From Neutral; Raises Target Price to $18 From $12","url":"https://stock-news.laohu8.com/highlight/detail?id=2491394686","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491394686?lang=en_us&edition=fundamental","pubTime":"2024-12-16 13:25","pubTimestamp":1734326727,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241216:nFWN3NE1F6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ZYME"],"gpt_icon":0},{"id":"2491142893","title":"U.S. RESEARCH ROUNDUP-Amazon, Broadcom, Exxon Mobil","url":"https://stock-news.laohu8.com/highlight/detail?id=2491142893","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491142893?lang=en_us&edition=fundamental","pubTime":"2024-12-13 15:08","pubTimestamp":1734073722,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Amazon, Broadcom, Exxon MobilDec 13 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Amazon, Broadc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241213:nL4N3NE0FB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CIEN","LU1923621640.USD","AES","MKSI","EDIT","BK4575","GLPI","SGXZ23171101.USD","LU1435385759.SGD","TOL","LU1201861165.SGD","LU0456854461.SGD","LU0130103400.USD","LU2108987350.USD","XOM","BOLD","LU1496350502.SGD","LU1150488135.SGD","LU0348723411.USD","ZYME","LU0107464264.USD","BK4512","USAW.SI","CHRW","WM","SRFM","FISI","MTH","IE00BZ9MQY76.HKD","LU1430597077.USD","BK4131","LU2023250330.USD","SAFE","CCS","LU0965509101.SGD","LU0942090050.USD","LU0878866978.SGD","LU1267930573.SGD","AMZN","SG9999015358.SGD","LU2236285917.USD","AVGO","LU0289961442.SGD","LU0965509010.AUD","LU0795875086.SGD","LU1720051108.HKD","IE00B3CCJ963.GBP","SG9999001440.SGD","DHI","LU1582987324.SGD"],"gpt_icon":1},{"id":"2490381555","title":"Zymeworks Advances Oncology and Expands Therapeutic Reach","url":"https://stock-news.laohu8.com/highlight/detail?id=2490381555","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490381555?lang=en_us&edition=fundamental","pubTime":"2024-12-12 22:08","pubTimestamp":1734012493,"startTime":"0","endTime":"0","summary":"Zymeworks (ZYME) has released an update. Zymeworks is making significant strides in its clinical pipeline, with plans to advance five drug candidat...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/zymeworks-advances-oncology-and-expands-therapeutic-reach?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/zymeworks-advances-oncology-and-expands-therapeutic-reach?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ZYME"],"gpt_icon":0},{"id":"2485666268","title":"PRESS DIGEST-Canada - Nov 22","url":"https://stock-news.laohu8.com/highlight/detail?id=2485666268","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485666268?lang=en_us&edition=fundamental","pubTime":"2024-11-22 21:26","pubTimestamp":1732281964,"startTime":"0","endTime":"0","summary":"PRESS DIGEST-Canada - Nov 22Nov 22 (Reuters) - The following are the top stories from a selected Canadian newspaper. Reuters has not verified these stories and does not vouch for their accuracy.THE GL","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nL4N3MT0Y2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JAZZ","LU0889565916.HKD","BK4533","BK4532","LU0109394709.USD","BK4007","ZYME","BK4139","LU0320765992.SGD"],"gpt_icon":0},{"id":"2485625164","title":"Zymeworks Price Target Maintained With a $12.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2485625164","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485625164?lang=en_us&edition=fundamental","pubTime":"2024-11-22 20:05","pubTimestamp":1732277100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ZYME/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 22, 2024 07:05 ET (12:05 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZYME"],"gpt_icon":0},{"id":"2485929784","title":"Zymeworks Shares up 2.8% After FDA Approves Co, Jazz Pharma's Biliary Tract Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2485929784","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485929784?lang=en_us&edition=fundamental","pubTime":"2024-11-21 22:32","pubTimestamp":1732199571,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nL4N3MS14M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ZYME"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zymeworks.com","stockEarnings":[{"period":"1week","weight":0.0511},{"period":"1month","weight":0.0691},{"period":"3month","weight":-0.0247},{"period":"6month","weight":0.4323},{"period":"1year","weight":0.2818},{"period":"ytd","weight":0.0253}],"compareEarnings":[{"period":"1week","weight":0.0149},{"period":"1month","weight":0.0285},{"period":"3month","weight":0.0409},{"period":"6month","weight":0.0999},{"period":"1year","weight":0.2145},{"period":"ytd","weight":0.0403}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.035465},{"month":2,"riseRate":0.375,"avgChangeRate":-0.054412},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.021688},{"month":4,"riseRate":0.571429,"avgChangeRate":0.031631},{"month":5,"riseRate":0.375,"avgChangeRate":0.035333},{"month":6,"riseRate":0.5,"avgChangeRate":-0.064157},{"month":7,"riseRate":0.375,"avgChangeRate":-0.034914},{"month":8,"riseRate":0.875,"avgChangeRate":0.094755},{"month":9,"riseRate":0.375,"avgChangeRate":0.024256},{"month":10,"riseRate":0.625,"avgChangeRate":0.033924},{"month":11,"riseRate":0.75,"avgChangeRate":0.102347},{"month":12,"riseRate":0.625,"avgChangeRate":0.007334}],"exchange":"NASDAQ","name":"ZYMEWORKS INC (US)","nameEN":"ZYMEWORKS INC (US)"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ZYMEWORKS INC (US)(ZYME),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ZYMEWORKS INC (US)(ZYME) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ZYMEWORKS INC (US),ZYME,ZYMEWORKS INC (US)股票,ZYMEWORKS INC (US)股票老虎,ZYMEWORKS INC (US)股票老虎国际,ZYMEWORKS INC (US)行情,ZYMEWORKS INC (US)股票行情,ZYMEWORKS INC (US)股价,ZYMEWORKS INC (US)股市,ZYMEWORKS INC (US)股票价格,ZYMEWORKS INC (US)股票交易,ZYMEWORKS INC (US)股票购买,ZYMEWORKS INC (US)股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ZYMEWORKS INC (US)(ZYME),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ZYMEWORKS INC (US)(ZYME) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}